All guidelines suggest the use of HMG-CoA inhibitors or statins for prevention of atherosclerotic cardiovascular disease. Recently, several concerns have been raised concerning the effects of these medications on endogenous steroid hormones production. The aim of this article is to review the impact of statins on endogenous sex hormones in order to elucidate their effect and safety in different clinical approaches. There are data suggesting that statins can slightly impair adrenal and/or gonadal steroid hormone synthesis. High-dose statins therapy might cause symptoms of hypogonadism, but reports have not indicated any harmful clinical effects of statins on spermatogenesis or erectile function. The possible negative effects of statins on erectile function due to a decrease in testosterone levels can be compensated for by their effect on inflammation and endothelial dysfunction. Statins have also an important role in the treatment of polycystic ovary syndrome (PCOS) in women. All these findings suggest that statins alter the production of endogenous sex hormones in both men and women without adequate evidence of harmful or adverse clinical side effects. Further studies are required to provide a clear clinical suggestion regarding this issue.
|Title of host publication
|Principles of Gender-Specific Medicine
|Subtitle of host publication
|Sex and Gender-Specific Biology in the Postgenomic Era
|Number of pages
|Published - 1 Jan 2023